OnCo

Follicular lymphoma: lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Locally advanced1
Advanced, first line2
Second line1

Locally advanced

SubgroupSettingApproachProducts and trialsEvidence
All comersLimited stage (I-II)Involved-site radiotherapy 24 Gy (FoRT); rituximab alone or observation in selected cases.91

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersAdvanced, low burden, asymptomaticWatch and wait (no survival penalty), or rituximab monotherapy to delay chemotherapy.83
All comersAdvanced, high burden (GELF criteria)Bendamustine-rituximab or bendamustine-obinutuzumab (GALLIUM), R-CHOP, or lenalidomide-rituximab (RELEVANCE); anti-CD20 maintenance 2 years (PRIMA).87

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersRelapsed (≥2 lines)Lenalidomide-rituximab (AUGMENT); CD20×CD3 bispecific (mosunetuzumab, epcoritamab); CD19 CAR-T (axi-cel, tisa-cel, liso-cel); zanubrutinib + obinutuzumab; clinical trials.83

Regimens in the library

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.